Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glycoprotein 41 (gp41) - Overview
Glycoprotein 41 (gp41) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glycoprotein 41 (gp41) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
Frontier Biotechnologies Inc
Longevity Biotech Inc
Minka Therapeutics SA
Molecular Express Inc
Mymetics Corp
vigen Inc
Novodux
Osel Inc
Protheragen Inc
Glycoprotein 41 (gp41) - Drug Profiles
albuvirtide LAR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPT-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human immunodeficiency virus (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-5001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Target GP120 and GP41 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Target GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPER-656 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MYMV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAC-3S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glycoprotein 41 (gp41) - Dormant Products
Glycoprotein 41 (gp41) - Discontinued Products
Glycoprotein 41 (gp41) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: vigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor
Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study
Aug 21, 2018: Frontier Biotech’s novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA
Jun 07, 2018: Frontier Biotech receives marketing authorization from Chi FDA for Aikening (albuvirtide for injection), Chi’s first new drug for the treatment of HIV
Sep 18, 2017: vigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
Jul 26, 2017: vigen Presents Promising Pre-Clinical Data on CPT31 at the 9th Intertiol AIDS Society Conference on HIV Science
Oct 20, 2016: Dr. Michael Kay Presents Recent Data on vigen’s HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
Aug 24, 2016: vigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
May 20, 2016: InVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functiol Cure in the US
Apr 11, 2016: Mymetics’ HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic
Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Frontier Biotechnologies Inc, H2 2020
Pipeline by Longevity Biotech Inc, H2 2020
Pipeline by Minka Therapeutics SA, H2 2020
Pipeline by Molecular Express Inc, H2 2020
Pipeline by Mymetics Corp, H2 2020
Pipeline by Navigen Inc, H2 2020
Pipeline by Novodux, H2 2020
Pipeline by Osel Inc, H2 2020
Pipeline by Protheragen Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020